Replimune to Resubmit Melanoma Drug for FDA Approval Following Leadership Changes

United States

Biotechnology company Replimune announced plans to resubmit its melanoma treatment for approval by the U.S. Food and Drug Administration (FDA), following leadership changes at the agency and renewed discussions regarding the drug's regulatory pathway.

The company said it has reached an understanding with the FDA on the next steps for the application and expects to submit the filing in the coming days.

New Regulatory Momentum

The development comes after the FDA previously rejected the treatment on two separate occasions. The latest move follows the departure of former FDA Commissioner Marty Makary earlier this month, a change that has prompted fresh engagement between regulators and the company.

Replimune stated that the agency has indicated the application will be treated as a priority matter, potentially accelerating the review process.

Dispute Over Clinical Trial Requirements

The melanoma therapy had become the center of a regulatory dispute between Replimune and the FDA. The company argued that the treatment represented an important option for patients with advanced skin cancer and maintained that it had followed an appropriate development pathway.

Regulators, however, previously expressed concerns regarding the clinical trial design and whether the company had adequately addressed earlier guidance provided during the approval process.

The disagreement drew attention across the biotechnology sector, with some drug developers raising concerns about what they viewed as inconsistent regulatory expectations surrounding clinical trials and approval standards.

Focus on Advanced Melanoma Patients

Replimune emphasized that the treatment is intended for patients with advanced melanoma who have already undergone anti-PD-1-based therapies and have limited remaining treatment options.

The company described its recent discussions with the FDA as constructive and said the renewed review process could represent an important opportunity for patients seeking additional treatment alternatives.

Shares Surge on Announcement

Investors reacted positively to the news, sending Replimune shares sharply higher in premarket trading. The stock surged by as much as 70% after the company disclosed its plans to move forward with a new submission.

The rally followed months of uncertainty surrounding the drug's regulatory future and reflected renewed optimism about the prospects for approval.

Replimune, which had a market capitalization of approximately $386 million before the announcement, is expected to provide further updates once the resubmission process is completed.